Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals logoLexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. LX1032 inhibits tryptophan hydroxylase (TPH), which is an orally-delivered small molecule compound that the Company is developing for the treatment of carcinoid syndrome. Sotagliflozin, or LX4211, which is an orally-delivered small molecule compound that the Company is developing for the treatment of type 1 and type 2 diabetes mellitus. LX2761 is an orally-delivered small molecule compound for the treatment of diabetes. LX9211 is an orally-delivered small molecule compound for the treatment of neuropathic pain. The Company's other programs include LX1033, LX2931 and LX7101.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: LXRX
  • CUSIP: 52887210
Key Metrics:
  • Previous Close: $18.37
  • 50 Day Moving Average: $16.34
  • 200 Day Moving Average: $14.42
  • 52-Week Range: $7.65 - $19.62
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.41
  • P/E Growth: -0.22
  • Market Cap: $1.93B
  • Outstanding Shares: 103,865,000
  • Beta: 1.33
Profitability:
  • Net Margins: -13.42%
  • Return on Equity: -9.03%
  • Return on Assets: -3.89%
Debt:
  • Debt-to-Equity Ratio: 0.39%
  • Current Ratio: 3.35%
  • Quick Ratio: 3.35%
Additional Links:
Companies Related to Lexicon Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Lexicon Pharmaceuticals (NASDAQ:LXRX) (?)
Ratings Breakdown: 3 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $22.42 (22.03% upside)
Analysts' Ratings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Show:
DateFirmActionRatingPrice TargetDetails
9/20/2016WedbushReiterated RatingOutperform$33.00View Rating Details
9/12/2016Needham & Company LLCReiterated RatingBuy$21.00View Rating Details
9/12/2016Citigroup Inc.Boost Price TargetBuy$21.00 -> $25.00View Rating Details
9/9/2016Cowen and CompanyReiterated RatingHoldView Rating Details
8/5/2016Stifel NicolausBoost Price TargetBuy$25.00 -> $26.00View Rating Details
5/5/2016JPMorgan Chase & Co.Reiterated RatingHold$16.00View Rating Details
9/28/2015GabelliUpgradeSell -> Hold$13.50View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016        
8/4/2016Q216($0.41)($0.37)$12.36 million$20.10 millionViewN/AView Earnings Details
5/3/2016Q1($0.30)($0.34)$11.11 million$12.50 millionViewN/AView Earnings Details
3/1/2016Q415($0.38)$0.76$21.50 million$127.30 millionViewN/AView Earnings Details
11/6/2015Q3($0.36)($0.34)$0.45 millionViewN/AView Earnings Details
8/7/2015Q215($0.32)($0.27)$0.45 million$376.00 millionViewN/AView Earnings Details
4/29/2015Q115($0.04)($0.04)$1.10 million$1.78 millionViewN/AView Earnings Details
11/4/2014Q3($0.05)($0.08)$0.16 million$0.40 millionViewN/AView Earnings Details
8/7/2014Q214($0.05)($0.05)$0.13 million$0.68 millionViewN/AView Earnings Details
5/8/2014Q114($0.05)($0.06)$0.12 million$277.00 millionViewN/AView Earnings Details
2/28/2014Q413($0.06)($0.03)$1.66 million$1.40 millionViewN/AView Earnings Details
11/12/2013Q3($0.01)($0.06)$1.59 million$0.24 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.05)($0.05)$0.37 million$0.22 millionViewN/AView Earnings Details
11/6/2012Q312($0.06)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Current Year EPS Consensus Estimate: $-1.5 EPS
Next Year EPS Consensus Estimate: $-1.61 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.37)($0.37)($0.37)
Q2 20161($0.35)($0.35)($0.35)
Q3 20161($0.46)($0.46)($0.46)
Q4 20161($0.18)($0.18)($0.18)
Q1 20171($0.63)($0.63)($0.63)
Q2 20171($0.59)($0.59)($0.59)
Q3 20171($0.48)($0.48)($0.48)
Q4 20171($0.51)($0.51)($0.51)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Lexicon Pharmaceuticals (NASDAQ:LXRX)
Insider Ownership Percentage: 5.40%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2016James F TessmerVPSell1,500$15.00$22,500.00View SEC Filing  
5/23/2016James F TessmerVPSell6,000$13.00$78,000.00View SEC Filing  
12/12/2014C.V. InvusDirectorBuy150,000$0.88$132,000.00View SEC Filing  
12/10/2014C.V. InvusDirectorBuy315,896$0.90$284,306.40View SEC Filing  
11/26/2014International S.C.A. ArtalDirectorBuy149,253,731$1.01$150,746,268.31View SEC Filing  
10/23/2012International S.C.A. ArtalDirectorBuy3,000,000$2.25$6,750,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Lexicon Pharmaceuticals (NASDAQ:LXRX)
DateHeadline
News IconBiotech news that matter for investors: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Agios Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:LXRX)
voiceregistrar.com - September 22 at 10:49 AM
News IconInteresting LXRX Put And Call Options For November 18th (NASDAQ:LXRX)
www.stockoptionschannel.com - September 20 at 11:08 AM
investorplace.com logo3 Big Stock Charts: Intel Corporation (INTC), Western Digital Corp (WDC) and Lexicon Pharmaceuticals, Inc. (LXRX) (NASDAQ:LXRX)
investorplace.com - September 19 at 10:30 AM
News IconLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Quarterly Analytical Analysis - Newburgh Press (NASDAQ:LXRX)
newburghpress.com - September 17 at 10:32 AM
News IconInstitutions Have Decreased Positions in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) - Post News (NASDAQ:LXRX)
www.kentuckypostnews.com - September 16 at 10:20 AM
News IconActive Biotech Stock News: Lexicon Pharmaceuticals, Inc. (LXRX), Vertex Pharmaceuticals Incorporated (VRTX) - The Independent Republic (NASDAQ:LXRX)
theindependentrepublic.com - September 16 at 10:20 AM
insidermonkey.com logoTwo Biotechs With Bad News This Week: What Happens Now? (NASDAQ:LXRX)
www.insidermonkey.com - September 16 at 10:20 AM
marketexclusive.com logoWhat Happened To FDA Review Of Lexicon Pharmaceuticals, Inc ... - Market Exclusive (NASDAQ:LXRX)
marketexclusive.com - September 15 at 4:01 PM
streetinsider.com logoLexicon Pharma (LXRX) Extends Telotristat Etiprate PDUFA Date Until February ... (NASDAQ:LXRX)
www.streetinsider.com - September 15 at 9:25 AM
marketexclusive.com logoWhat Happened To FDA Review Of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Telotristat Etiprate? (NASDAQ:LXRX)
marketexclusive.com - September 15 at 9:25 AM
rttnews.com logoLexicon Pharmaceuticals (LXRX) Jumped To A New High On Phase 3 Study Results - RTT News (NASDAQ:LXRX)
www.rttnews.com - September 14 at 6:07 PM
insidermonkey.com logoDelving Into The Lexicon Pharmaceuticals, Inc. (LXRX) Data - Insider Monkey (blog) (NASDAQ:LXRX)
www.insidermonkey.com - September 14 at 6:07 PM
fool.com logoIs This Lexicon Pharmaceuticals' Year? (NASDAQ:LXRX)
www.fool.com - September 13 at 3:28 PM
News IconLexicon Pharmaceuticals Inc. (LXRX) PT Raised to $25.00 at Citigroup Inc (NASDAQ:LXRX)
magseriesusa.net - September 13 at 10:53 AM
capitalcube.com logoLexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : September 12, 2016 (NASDAQ:LXRX)
www.capitalcube.com - September 12 at 5:50 PM
finance.yahoo.com logoLexicon Pharmaceuticals (LXRX) Jumps: Stock Rises 16.6% (NASDAQ:LXRX)
finance.yahoo.com - September 12 at 10:41 AM
benzinga.com logoFinisar Corporation (NASDAQ:FNSR), Lexicon Pharmaceuticals, Inc ... - Benzinga (NASDAQ:LXRX)
www.benzinga.com - September 11 at 10:12 AM
marketwatch.com logoLexicon Pharma shares rally 48% premarket on positive trial of diabetes treatment - MarketWatch (NASDAQ:LXRX)
www.marketwatch.com - September 11 at 10:12 AM
thecountrycaller.com logoLexicon Pharmaceuticals, Inc. (LXRX) Affirmed as Buy On Positive ... - TCC (NASDAQ:LXRX)
www.thecountrycaller.com - September 11 at 10:12 AM
News IconWhy El Pollo LoCo Holdings, Lexicon Pharmaceuticals and Restoration Hardware Holdings Are 3 of Today's Best Stocks (NASDAQ:LXRX)
www.minyanville.com - September 10 at 10:21 AM
investorplace.com logoIt was a miserable day for stocks, but this trio avoided the carnage (NASDAQ:LXRX)
investorplace.com - September 10 at 10:21 AM
thecountrycaller.com logoLexicon Pharmaceuticals, Inc. (LXRX) Affirmed as Buy On Positive Sotagliflozin Trials: Needham (NASDAQ:LXRX)
www.thecountrycaller.com - September 10 at 10:21 AM
fool.com logoWhy Lexicon Pharmaceuticals Skyrocketed 17% Today (NASDAQ:LXRX)
www.fool.com - September 9 at 5:46 PM
News IconInstitutional Investors Have Decreased Positions in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) (NASDAQ:LXRX)
www.nationaldailypress.com - September 9 at 10:46 AM
streetinsider.com logoLexicon Pharma (LXRX) Announces Sotagliflozin Phase 3 in T1D Met Primary Endpoint (NASDAQ:LXRX)
www.streetinsider.com - September 9 at 10:46 AM
schaeffersresearch.com logoBuzz Stocks: Kroger Co, Lexicon Pharmaceuticals, Inc., and Restoration Hardware Holdings Inc (NASDAQ:LXRX)
www.schaeffersresearch.com - September 9 at 10:46 AM
smarteranalyst.com logoStock Update (NASDAQ:LXRX): Lexicon Pharmaceuticals, Inc. Reports Positive Top ... (NASDAQ:LXRX)
www.smarteranalyst.com - September 9 at 10:46 AM
News IconDiabetes Trial Data Gives Lexicon Pharma (LXRX) a 21% Boost (NASDAQ:LXRX)
www.economiccalendar.com - September 9 at 10:46 AM
rttnews.com logoLexicon Pharmaceuticals Inc. (LXRX) Has Surged To A New High On Phase 3 Results (NASDAQ:LXRX)
www.rttnews.com - September 9 at 10:46 AM
finance.yahoo.com logo6:59 am Lexicon Pharma reports that the pivotal inTandem1 Phase 3 clinical trial of sotagliflozin met its primary endpoint (NASDAQ:LXRX)
finance.yahoo.com - September 9 at 10:46 AM
publicnow.com logoLexicon Reports Positive Top-line Results in Pivotal Phase 3 Study for Sotagliflozin in Patients with Type 1 Diabetes (NASDAQ:LXRX)
www.publicnow.com - September 9 at 10:46 AM
marketwatch.com logoLexicon Pharma shares rally 48% premarket on positive trial of diabetes treatment (NASDAQ:LXRX)
www.marketwatch.com - September 9 at 10:46 AM
capitalcube.com logoLexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US : September 9, 2016 (NASDAQ:LXRX)
www.capitalcube.com - September 9 at 10:45 AM
247wallst.com logoWhy Lexicon Pharma Is Soaring (NASDAQ:LXRX)
247wallst.com - September 9 at 10:45 AM
investors.com logoStocks Fall On Rate Jitters; S&P 500 Breaches 50-Day Line (NASDAQ:LXRX)
www.investors.com - September 9 at 10:45 AM
News IconPlacing Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares Under the Microscope - Post News (NASDAQ:LXRX)
www.kentuckypostnews.com - September 8 at 5:52 PM
News IconStock Sliding Down Over the Last Month: Lexicon Pharmaceuticals ... - Post News (NASDAQ:LXRX)
www.kentuckypostnews.com - September 8 at 5:52 PM
News IconLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) missed earnings on 2 occasions - The Independent Republic (NASDAQ:LXRX)
theindependentrepublic.com - September 8 at 5:52 PM
News IconNews review of 2 biotech stocks: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Corbus Pharmaceuticals Holdings ... - The Voice Registrar (NASDAQ:LXRX)
voiceregistrar.com - September 8 at 5:52 PM
finance.yahoo.com logoLexicon To Present At The Bank Of America Merrill Lynch Global Health Care Conference (NASDAQ:LXRX)
finance.yahoo.com - September 7 at 6:12 PM
News IconStock Struggling for the Quarter: Lexicon Pharmaceuticals, Inc ... - Post News (NASDAQ:LXRX)
www.kentuckypostnews.com - September 3 at 5:28 PM
News IconWhich way Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) earnings may go - The Voice Registrar (NASDAQ:LXRX)
voiceregistrar.com - August 30 at 9:20 AM
capitalcube.com logoETF’s with exposure to Lexicon Pharmaceuticals, Inc. : August 26, 2016 (NASDAQ:LXRX)
www.capitalcube.com - August 26 at 5:49 PM
capitalcube.com logoLexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US : August 25, 2016 (NASDAQ:LXRX)
www.capitalcube.com - August 25 at 11:05 AM
finance.yahoo.com logoLEXICON PHARMACEUTICALS, INC. Financials (NASDAQ:LXRX)
finance.yahoo.com - August 12 at 6:07 PM
mysmartrend.com logoLexicon Pharmaceuticals Up 40.8% Since SmarTrend Uptrend Call (LXRX) (NASDAQ:LXRX)
www.mysmartrend.com - August 11 at 6:24 PM
streetupdates.com logoAnalysts Suggestion Alert: XOMA Corporation (NASDAQ:XOMA ... - Street Updates (NASDAQ:LXRX)
www.streetupdates.com - August 6 at 8:53 AM
finance.yahoo.com logoEdited Transcript of LXRX earnings conference call or presentation 4-Aug-16 2:00pm GMT (NASDAQ:LXRX)
finance.yahoo.com - August 5 at 6:13 PM
biz.yahoo.com logoLEXICON PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:LXRX)
biz.yahoo.com - August 4 at 6:22 PM
twst.com logoLexicon Pharmaceuticals Inc.: Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2016 Second Quarter Financial Results (NASDAQ:LXRX)
www.twst.com - August 4 at 9:07 AM

Social

Lexicon Pharmaceuticals (NASDAQ:LXRX) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff